Abiopharma

🔍 Malik Kemal (Director)

Company: Cartesian Therapeutics, Inc. (RNAC)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Acquired 2,600 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 11,133.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 7,800 shares of Stock Option (Right to Buy) at $6.76 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-01 | Exercise: 2027-01-02 | equity_swap_involved: 0 | shares_owned_after: 7,800.00 | transaction_form_type: 4

Footnotes:

• F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027.